Asthma drug could shield hearts after attack, new trial hopes
NCT ID NCT07320625
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether montelukast, a common asthma drug, can reduce heart damage in people having a heart attack. 512 patients with a specific type of heart attack will receive either montelukast or a placebo daily for 3 months. The goal is to see if the drug prevents the heart from becoming enlarged and weak after blood flow is restored.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Montelukast
What this could lead to
If it works, this could point toward a new, low-cost way to prevent heart failure after a heart attack by reducing injury when blood flow is restored.
What could go wrong
This is a phase 3 trial, but montelukast is being repurposed for a new use, and previous studies have been small or in animals. It may not show clear benefit in humans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOCARDIAL INFARCTION (MI) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Zhongshan Hospital of Dalian University
RECRUITINGDalian, Liaoning, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Fujian provincial hospital
RECRUITINGFuzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Guangdong Provincial People's Hospital
RECRUITINGGuangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Harbin Medical University Second Affiliated Hospital
RECRUITINGHa’erbin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hunan Provincial People's Hospital
RECRUITINGHunan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Liaoning Provincial People's Hospital
RECRUITINGShenyang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The 2nd Affiliated Hospital and Yuying Children's Hospital of WMU
RECRUITINGWenzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital of the University of Science and Technology of China
RECRUITINGHefei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Second Affiliated Hospital of Dalian Medical University
RECRUITINGDalian, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Second Xiangya Hospital of Central South University
RECRUITINGHunan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Xiangya Hospital of Central South University
RECRUITINGHunan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Zhongshan Hospital, Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••